Revance Therapeutics, Inc. - RVNC STOCK NEWS

Revance Therapeutics (RVNC) announced a proposed underwritten public offering of $150 million of its common stock, with a potential for an additional 15% from underwriters. The proceeds will fund commercialization of DAXXIFY™, the RHA® Collection, and OPUL®, alongside general corporate purposes. The offering is subject to market conditions and completion is not guaranteed. Goldman Sachs, Cowen, Guggenheim Securities, and Barclays are managing the offering. The offering is being made under an automatic shelf registration statement.

Revance Therapeutics, Inc. (RVNC) has received FDA approval for DAXXIFY™ (daxibotulinumtoxinA-lanm), the first long-acting neuromodulator for treating moderate to severe frown lines in adults. This product showcases a median efficacy duration of six months, with some patients experiencing results lasting up to nine months. DAXXIFY™ is formulated with Peptide Exchange Technology™ and does not contain animal-derived components. The approval strengthens Revance's position in the $3.2 billion U.S. facial injectables market and indicates potential for future therapeutic applications.

Revance Therapeutics (Nasdaq: RVNC) reported a strong second quarter 2022, achieving total revenue of $28.4 million, up 51% from $18.8 million in Q2 2021. The RHA® Collection contributed $25.5 million to this total. Selling, general, and administrative expenses decreased to $47.8 million due to cost management. Additionally, R&D expenses fell to $24.9 million.

The company anticipates a PDUFA date of September 8, 2022, for DaxibotulinumtoxinA, with hopes for future growth fueled by the recent launch of RHA® Redensity.

Revance Therapeutics, Inc. (NASDAQ: RVNC) is set to release its Q2 2022 financial results on August 9, 2022, after market close. A conference call and live webcast will follow at 4:30 p.m. ET to discuss the results and provide a business update. Revance specializes in innovative aesthetic and therapeutic solutions, including its leading product, DaxibotulinumtoxinA for injection, which is under U.S. regulatory review after successful Phase 3 trials. The company also holds exclusive distribution rights for the RHA® Collection of dermal fillers.

Revance Therapeutics (RVNC) announced new data on RTP004, enhancing membrane binding of BoNT/A, during a podium presentation at the TOXINS International Conference. The ASPEN-1 Phase 3 trial results for DaxibotulinumtoxinA for cervical dystonia were presented by Dr. Cynthia Comella. The company emphasizes its commitment to neurotoxin research and the therapeutic pipeline's potential. Revance is advancing its long-acting neuromodulator, currently under U.S. regulatory review, while targeting aesthetic and therapeutic markets.

Revance Therapeutics, Inc. (Nasdaq: RVNC) will participate in the William Blair 42nd Annual Growth Stock Conference from June 6-9 in Chicago. CEO Mark Foley is set to present on June 6 at 2:00 p.m. CT. Interested parties can access the live audio webcast on the company’s website, with a replay available for 90 days post-event. Revance focuses on innovative aesthetic and therapeutic products, including the long-acting neuromodulator DaxibotulinumtoxinA for Injection, currently pursuing U.S. regulatory approval for use in glabellar lines and cervical dystonia.

Revance Therapeutics (RVNC) reported strong Q1 2022 results, with total revenue soaring 89.9% to $25.3 million. This surge was driven by the RHA® Collection, generating $20.8 million, up 78.9% year-over-year. The company also secured a $300 million note purchase agreement, enhancing its financial prospects, while total operating expenses amounted to $87.5 million, resulting in a net loss of $64.3 million. A critical PDUFA date for DaxibotulinumtoxinA for injection has been set for September 8, 2022.

Revance Therapeutics (NASDAQ: RVNC) announced it will release its first-quarter financial results on May 10, 2022, after market close. A conference call to discuss these results and provide a business update is scheduled for 1:30 p.m. PT the same day. Revance focuses on innovative aesthetic and therapeutic products, including DaxibotulinumtoxinA for Injection, which is under U.S. regulatory review for glabellar lines. The company also holds exclusive U.S. distribution rights for the RHA® Collection of dermal fillers.

Revance Therapeutics, Inc. (NASDAQ: RVNC) announced the FDA's acceptance of its Biologics License Application (BLA) resubmission for DaxibotulinumtoxinA for Injection, targeting moderate to severe glabellar lines. The BLA has been classified as a Class 2 resubmission, indicating a six-month review period, with a PDUFA goal date of September 8, 2022. The company completed Phase 3 clinical trials for this product and is pursuing U.S. regulatory approval. Additionally, Revance continues to develop a biosimilar to BOTOX® in collaboration with Viatris.